Curaleaf Posts Record Revenue but Faces Margin Pressure
Event summary
- Curaleaf reported Q3 2026 revenue of $353M, up 11% YoY, with international revenue growing 28% YoY to $59M.
- Adjusted gross profit margin declined 186 basis points YoY to 48.7%, while adjusted EBITDA margin fell 56 basis points to 22%.
- The company expanded its retail footprint to 191 dispensaries, including new openings in Florida and New Jersey.
- Curaleaf launched an offer to acquire Aurora Cannabis, later enhancing the bid amid Aurora's merger plans with Organigram.
- Cash position stood at $105M, with $637M in outstanding debt and $50M invested in capital expenditures over nine months.
The big picture
Curaleaf's Q3 results highlight the tension between revenue growth and margin erosion, a common challenge in the cannabis sector. The company's aggressive retail expansion and international push come as U.S. federal regulations remain a hurdle. The Aurora acquisition attempt underscores Curaleaf's ambition to consolidate the fragmented market, but success hinges on navigating regulatory and competitive obstacles.
What we're watching
- Margin Sustainability
- Whether Curaleaf can stabilize declining gross margins amid rising operational costs and competitive pressures.
- Acquisition Strategy
- How Curaleaf's pursuit of Aurora Cannabis will unfold against Organigram's competing merger proposal.
- International Expansion
- The pace at which Curaleaf can scale its international segment, particularly in Europe, to offset domestic challenges.
